Donnie McGrath | Head of Corporate Strategy & Business Development
Biohaven Pharmaceuticals

Donnie McGrath, Head of Corporate Strategy & Business Development, Biohaven Pharmaceuticals

Dr. McGrath has over 22 years of clinical research and pharmaceutical business development experience. From 2013 to 2017, he was Vice President, Business Development, and Head of Search & Evaluation at Bristol-Myers Squibb, based in Princeton, NJ. During this period, the business development group executed over 50 major transactions in the therapeutic areas of oncology, neuroscience, cardiovascular, fibrosis, immuno-science, virology, and genetically-defined diseases. In addition, Dr. McGrath was responsible for overseeing BMS’ venture capital investment portfolio and provided leadership for all global external partnering activities. From 2010 to 2013, he was Executive Director in Business Development responsible for neuroscience and virology business development. In 2005, he joined the BMS virology clinical development group based in Wallingford, CT, as a director of clinical research, and became Group Director in 2007 and the REYATAZ® Development Lead. Dr. McGrath oversaw multiple clinical virology programs resulting in seven major FDA filings for REYATAZ® and SUSTIVA®, and over 60 EMEA procedures submitted and fulfilled. From 1998 to 2005, he was a physician-researcher in the Division of Geographic Medicine and Infectious Disease at Tufts-New England Medical Center, and an Assistant Professor of Medicine at Tufts Medical School in Boston. From 2002-2004 he was based at the Africa Center for Reproductive Health and Population Studies in KwaZulu Natal, South Africa, where he established an NIH-funded post-graduate training program in medical informatics with the University of KwaZulu Natal School of Medicine and worked on HIV clinical studies. Dr. McGrath earned his undergraduate degree at University College Dublin, his medical degree from the Royal College of Surgeons in Ireland, and his MPH from the Harvard School of Public Health. He completed his residency in internal medicine at St. Elizabeth’s Medical Center, and fellowship in Infectious Disease at Tufts-New England Medical Center, both in Boston.


World Orphan Drug Congress USA 2018 - Conference Day Two @ 12:05

Glutamate modulating medicines for the treatment of rare neurologic diseases

back to speakers